Phase I clinical study with 5 peptides vaccination in HLA-A2402-positive advanced-stage esophageal cancer patients

Phase I clinical study with 5 peptides vaccination in HLA-A2402-positive advanced-stage esophageal cancer patients - Clinical study with multi-peptides vaccination in esophageal cancer patients

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004714

Enrollment

Registered

2010-12-14

Start date

2008-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chemotherapy-resistance unresectable esophageal cancer

Interventions

URLC10,TTK,KOC1,VEGFR1,VEGFR2-derived peptide vaccine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)pathologicaly diagnosed esophagal squamous cell carcinoma 2)unresectable and refractory for standard chemotherapy 3)Performance status(ECOG) 0,1,2 4)obtains lesionthat can be evaluated by RECIST 5)more than 4 weeks after prior therapy 6)WBC >=2000, <=15000 Platelet>=50000 Total Bilirubin<=3.3 Creatinine<=2.2 7)HLA-A*24:02 8)obtains writen informed consent

Exclusion criteria

Exclusion criteria: 1)severe comorbidity(cardiovascular disease, respiratory disease, infectious disease) 2)pregnant woman 3)systemic administration of immunosuppressant

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
immunological responce tumor regression survival time	—

Countries

Japan

Contacts

Public ContactMinoru Nakui

Tokai University School of Medicine Department of Gastroenterological Surgery

nakui@is.icc.u-tokai.ac.jp0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026